vs
Side-by-side financial comparison of QVC Group, Inc. (QVCGA) and Viatris (VTRS). Click either name above to swap in a different company.
Viatris is the larger business by last-quarter revenue ($3.7B vs $2.7B, roughly 1.4× QVC Group, Inc.). On growth, Viatris posted the faster year-over-year revenue change (5.0% vs -9.1%). Viatris produced more free cash flow last quarter ($619.3M vs $191.0M). Over the past eight quarters, QVC Group, Inc.'s revenue compounded faster (6.9% CAGR vs 0.5%).
QVC Group, is an American media conglomerate controlled by company chairman John C. Malone, who owns a majority of the voting shares.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
QVCGA vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.7B | $3.7B |
| Net Profit | $-37.0M | — |
| Gross Margin | 32.9% | 31.1% |
| Operating Margin | 3.7% | -5.2% |
| Net Margin | -1.4% | — |
| Revenue YoY | -9.1% | 5.0% |
| Net Profit YoY | 97.1% | — |
| EPS (diluted) | $-17.37 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.7B | $3.7B | ||
| Q3 25 | $2.2B | $3.7B | ||
| Q2 25 | $2.2B | $3.6B | ||
| Q1 25 | $2.1B | $3.2B | ||
| Q4 24 | $2.9B | $3.5B | ||
| Q3 24 | $2.3B | $3.7B | ||
| Q2 24 | $2.4B | $3.8B | ||
| Q1 24 | $2.3B | $3.7B |
| Q4 25 | $-37.0M | — | ||
| Q3 25 | $-80.0M | — | ||
| Q2 25 | $-2.2B | — | ||
| Q1 25 | $-100.0M | — | ||
| Q4 24 | $-1.3B | — | ||
| Q3 24 | $-23.0M | — | ||
| Q2 24 | $20.0M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | 32.9% | 31.1% | ||
| Q3 25 | 34.0% | 36.6% | ||
| Q2 25 | 36.4% | 37.3% | ||
| Q1 25 | 34.2% | 35.8% | ||
| Q4 24 | 33.3% | 34.6% | ||
| Q3 24 | 35.3% | 39.0% | ||
| Q2 24 | 36.4% | 38.2% | ||
| Q1 24 | 35.5% | 41.2% |
| Q4 25 | 3.7% | -5.2% | ||
| Q3 25 | 2.7% | 4.8% | ||
| Q2 25 | -101.6% | 6.5% | ||
| Q1 25 | 0.7% | -88.9% | ||
| Q4 24 | -43.2% | -5.1% | ||
| Q3 24 | 6.5% | 6.0% | ||
| Q2 24 | 6.9% | -6.3% | ||
| Q1 24 | 6.2% | 5.6% |
| Q4 25 | -1.4% | — | ||
| Q3 25 | -3.6% | — | ||
| Q2 25 | -99.4% | — | ||
| Q1 25 | -4.8% | — | ||
| Q4 24 | -43.7% | — | ||
| Q3 24 | -1.0% | — | ||
| Q2 24 | 0.8% | — | ||
| Q1 24 | -0.0% | — |
| Q4 25 | $-17.37 | $-0.34 | ||
| Q3 25 | $-9.89 | $-0.11 | ||
| Q2 25 | $-275.46 | $0.00 | ||
| Q1 25 | $-0.25 | $-2.55 | ||
| Q4 24 | — | $-0.43 | ||
| Q3 24 | $-0.06 | $0.08 | ||
| Q2 24 | $2.57 | $-0.27 | ||
| Q1 24 | — | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $1.3B |
| Total DebtLower is stronger | $790.0M | — |
| Stockholders' EquityBook value | $-3.1B | $14.7B |
| Total Assets | $7.6B | $37.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $1.8B | $975.3M | ||
| Q2 25 | $897.0M | $566.4M | ||
| Q1 25 | $833.0M | $755.0M | ||
| Q4 24 | $905.0M | $734.8M | ||
| Q3 24 | $873.0M | $1.9B | ||
| Q2 24 | $1.2B | $917.2M | ||
| Q1 24 | $1.1B | $1.0B |
| Q4 25 | $790.0M | — | ||
| Q3 25 | $5.9B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $5.0B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $5.1B | — | ||
| Q2 24 | $5.3B | — | ||
| Q1 24 | $5.5B | — |
| Q4 25 | $-3.1B | $14.7B | ||
| Q3 25 | $-3.1B | $15.2B | ||
| Q2 25 | $-3.0B | $15.6B | ||
| Q1 25 | $-981.0M | $15.7B | ||
| Q4 24 | $-971.0M | $18.6B | ||
| Q3 24 | $397.0M | $19.8B | ||
| Q2 24 | $328.0M | $19.5B | ||
| Q1 24 | $255.0M | $20.0B |
| Q4 25 | $7.6B | $37.2B | ||
| Q3 25 | $7.6B | $37.9B | ||
| Q2 25 | $6.7B | $38.4B | ||
| Q1 25 | $9.0B | $38.5B | ||
| Q4 24 | $9.2B | $41.5B | ||
| Q3 24 | $10.8B | $44.8B | ||
| Q2 24 | $10.9B | $45.3B | ||
| Q1 24 | $11.0B | $47.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 12.74× | — | ||
| Q2 24 | 16.28× | — | ||
| Q1 24 | 21.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $244.0M | $815.8M |
| Free Cash FlowOCF − Capex | $191.0M | $619.3M |
| FCF MarginFCF / Revenue | 7.1% | 16.8% |
| Capex IntensityCapex / Revenue | 2.0% | 5.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $118.0M | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $244.0M | $815.8M | ||
| Q3 25 | $4.0M | $744.9M | ||
| Q2 25 | $86.0M | $219.7M | ||
| Q1 25 | $-60.0M | $535.5M | ||
| Q4 24 | $212.0M | $482.7M | ||
| Q3 24 | $20.0M | $826.5M | ||
| Q2 24 | $267.0M | $379.1M | ||
| Q1 24 | $26.0M | $614.6M |
| Q4 25 | $191.0M | $619.3M | ||
| Q3 25 | $-27.0M | $658.1M | ||
| Q2 25 | $48.0M | $166.8M | ||
| Q1 25 | $-94.0M | $492.9M | ||
| Q4 24 | $150.0M | $342.3M | ||
| Q3 24 | $-23.0M | $749.5M | ||
| Q2 24 | $213.0M | $320.3M | ||
| Q1 24 | $-14.0M | $564.8M |
| Q4 25 | 7.1% | 16.8% | ||
| Q3 25 | -1.2% | 17.6% | ||
| Q2 25 | 2.1% | 4.7% | ||
| Q1 25 | -4.5% | 15.2% | ||
| Q4 24 | 5.1% | 9.7% | ||
| Q3 24 | -1.0% | 20.1% | ||
| Q2 24 | 8.8% | 8.5% | ||
| Q1 24 | -0.6% | 15.5% |
| Q4 25 | 2.0% | 5.3% | ||
| Q3 25 | 1.4% | 2.3% | ||
| Q2 25 | 1.7% | 1.5% | ||
| Q1 25 | 1.6% | 1.3% | ||
| Q4 24 | 2.1% | 4.0% | ||
| Q3 24 | 1.8% | 2.1% | ||
| Q2 24 | 2.2% | 1.6% | ||
| Q1 24 | 1.7% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 13.35× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QVCGA
| Other | $915.0M | 34% |
| Home | $754.0M | 28% |
| Beauty | $260.0M | 10% |
| Apparel | $254.0M | 9% |
| Electronics | $187.0M | 7% |
| Accessories | $181.0M | 7% |
| Jewelry | $87.0M | 3% |
| Manufactured Product Other | $38.0M | 1% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
